Lantheus Holdings Inc. (LNTH) Shares Down 10.6%
Lantheus Holdings Inc. (NASDAQ:LNTH) fell 10.6% on Tuesday . The stock traded as low as $6.63 and last traded at $7.32, with a volume of 665,817 shares changing hands. The stock had previously closed at $8.19.
Several research firms recently weighed in on LNTH. Zacks Investment Research downgraded Lantheus Holdings from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Jefferies Group reissued a “buy” rating on shares of Lantheus Holdings in a report on Wednesday, May 4th. Finally, Credit Suisse Group AG set a $4.00 price objective on Lantheus Holdings and gave the company a “hold” rating in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Lantheus Holdings has an average rating of “Buy” and a consensus price target of $5.80.
The company has a market capitalization of $224.26 million and a price-to-earnings ratio of 8.33. The stock has a 50-day moving average of $5.18 and a 200 day moving average of $2.97.
Lantheus Holdings (NASDAQ:LNTH) last issued its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. The business had revenue of $78 million for the quarter, compared to the consensus estimate of $72.66 million. On average, equities research analysts anticipate that Lantheus Holdings Inc. will post $0.53 earnings per share for the current year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.